Skip To Main Content
Sally Baron-Hay on Muck Rack

Sally Baron-Hay

As seen in: Color Research & Application, Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sally

Contact Sally, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2 : phase 2 EMBRACE trial

|
By Katrin M. Sjoquist, Alexander Dobrovic, Kristy P. Robledo, Ksenija Nesic, Sally Baron-Hay, Nicole McCarthy, Jeffrey Goh, Christopher Steer, Sonia Yip, Linda Mileshkin, J. Lynn Fink, Lisa Bailey, Yvonne Lee, Danka S Zebic, Kristy Shield-Artin, Anthony T. Papenfuss, Olga Kondrashova, Matthew Wakefield, Cassandra J. Vandenberg, Martin R. Stockler, Clare Scott Verified, Paul M. Waring, Sumitra Ananda, Garry Chang, U. G. Imalki U. Kariyawasam, Andrew Jarratt
| Nature Verified
Abstract Homologous recombination (HR) deficiency (HRD) from germline BRCA1/2 mutations (gBRCAm) sensitizes high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC) to PARP inhibitors (PARPi), as may promoter methylation of BRCA1 (meBRCA1) or RAD51C (meRAD51C) or mutation of non-BRCA HR genes. This trial evaluated olaparib in platinum-sensitive, relapsed HGSOC (PSROC) and metastatic TNBC (mTNBC) with non-gBRCA HRD.
Open in Who Shared Issue with article?

Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial | Nature Communications

|
By Chee Khoon Lee, Nirashaa T. Bound, Katherine Francis, Kristy Shield-Artin, Justin Bedo, Ksenija Nesic, Claire Holly Davies, Emily Cassar, Hina Amer, Sally Baron-Hay, Sandy Simon, Anthony T. Papenfuss, Matthew Wakefield, Cassandra J. Vandenberg, Michael Friedlander, Clare Scott Verified
| Nature Verified
Abstract SOLACE2 (ACTRN12618000686202) investigates whether 12-weeks of olaparib, or cyclophosphamide-olaparib priming, improves subsequent durvalumab-olaparib progression-free survival (PFS), and is superior to olaparib monotherapy without any priming, in platinum-sensitive recurrent ovarian cancer (n = 114). We also evaluate the utility of CUP-CC assay, an immune signature of C-C chemokine receptor type 4 up-regulation, chemokines, and cytokines.
Open in Who Shared Issue with article?

Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial - Nature Medicine

|
By Nadia Harbeck, Eva Ciruelos, Roisin M. Connolly, Sally Baron-Hay, Giampaolo Bianchini, Hans Wildiers, Nancy Lin
| Nature Verified
Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03261-7, published online 13 September 2024. In the version of this article initially published, members of the DESTINY-Breast12 study group were not included by the journal in the full text. In Table 1, under the “Prior CNS therapies n (%)” section, seven rows have been added, in addition to the original CNS radiotherapy, WBRT and SRS rows.
Open in Who Shared View Duplicates (6) Issue with article?
See all 5 articles